Bavarian Nordic A/S (BVNRY)
Market Cap | 1.94B |
Revenue (ttm) | 960.71M |
Net Income (ttm) | 142.34M |
Shares Out | 233.80M |
EPS (ttm) | 1.99 |
PE Ratio | 13.83 |
Forward PE | 4.99 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 198 |
Open | 8.28 |
Previous Close | 8.30 |
Day's Range | n/a |
52-Week Range | 5.95 - 9.62 |
Beta | 1.42 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About BVNRY
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phas... [Read more]
News
![](https://cdn.snapi.dev/images/v1/p/r/press13-2504335.jpg)
Bavarian Nordic Converts Existing Credit Facility into Sustainability-linked Loan
COPENHAGEN, Denmark, July 1, 2024 – Bavarian Nordic today announced the conversion of its existing undrawn DKK 1 billion syndicated revolving credit facility (RCF) into a sustainability-linked loan (S...
![](https://cdn.snapi.dev/images/v1/p/r/press7-2502050.jpg)
Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa
COPENHAGEN, Denmark, June 28, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an extended commitment to help fight the current mpox outbreak in Africa. The Company's MVA-BN vaccine, the only FD...
![](https://cdn.snapi.dev/images/v1/p/r/press17-2497106.jpg)
Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA
COPENHAGEN, Denmark, June 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approv...
![](https://cdn.snapi.dev/images/v1/p/r/press4-2482232.jpg)
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate
COPENHAGEN, Denmark, June 17, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the rolling submission process which was initiated in April 2024 with the U.S. Food and Drug Admi...
![](https://cdn.snapi.dev/images/v1/p/r/press1-2456502.jpg)
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
COPENHAGEN, Denmark, May 31, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA)...
![](https://cdn.snapi.dev/images/v1/p/r/press18-2453558.jpg)
Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa
COPENHAGEN, Denmark / OSLO, Norway, May 30, 2024 – Bavarian Nordic A/S (OMX: BAVA) and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced a partnership to advance the developme...
![](https://cdn.snapi.dev/images/v1/p/r/press13-2443122.jpg)
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
COPENHAGEN, Denmark, May 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 187,020 as a consequence of employees' exercise...
![](https://cdn.snapi.dev/images/v1/p/r/press10-2442665.jpg)
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
COPENHAGEN, Denmark, May 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on May 8, 2024, has now been terminated, as the intende...
![](https://cdn.snapi.dev/images/v1/p/r/press20-2441345.jpg)
EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic
COPENHAGEN, Denmark, May 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that Laurence de Moerlooze will leave her position as Executive Vice President and Chief Medical Officer in the Comp...
![](https://cdn.snapi.dev/images/v1/p/r/press19-2418009.jpg)
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
COPENHAGEN, Denmark, May 8, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a new share buy-back program, under which the Company intends to buy back up to 162,288 of its own ...
![](https://cdn.snapi.dev/images/v1/p/r/press17-2418008.jpg)
Bavarian Nordic Announces Interim Results for the First Three Months of 2024
COPENHAGEN, Denmark , May 8, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2024.
![](https://cdn.snapi.dev/images/v1/p/r/press5-2416233.jpg)
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, May 7, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding manager...
![](https://cdn.snapi.dev/images/v1/p/r/press18-2398131.jpg)
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN® smallpox vaccine to the strategic reserve w...
![](https://cdn.snapi.dev/images/v1/p/r/press7-2397214.jpg)
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biolog...
![](https://cdn.snapi.dev/images/v1/p/r/press7-2374224.jpg)
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S
COPENHAGEN, Denmark, April 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results:
![](https://cdn.snapi.dev/images/v1/p/r/press3-2354312.jpg)
Morris & Dickson is the First U.S. Distributor for Bavarian Nordic's JYNNEOS®, the Only FDA-approved Mpox Vaccine
SHREVEPORT, La.--(BUSINESS WIRE)--Morris & Dickson is proud to announce it is the first U.S. distributor of Bavarian Nordic's newly launched mpox vaccine, JYNNEOS®. As the only FDA-approved mpox vacci...
![](https://cdn.snapi.dev/images/v1/p/r/press3-2351921.jpg)
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant...
![](https://cdn.snapi.dev/images/v1/p/r/press20-2334934.jpg)
Bavarian Nordic A/S – Notice Convening Annual General Meeting
COPENHAGEN, Denmark, March 21, 2024 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on
![](https://cdn.snapi.dev/images/v1/p/r/press12-2322146.jpg)
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland
COPENHAGEN, Denmark, March 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS® (MVA-BN) for active immunization...
![](https://cdn.snapi.dev/images/v1/p/r/press17-2310153.jpg)
Bavarian Nordic Publishes Annual Report 2023
COPENHAGEN, Denmark, March 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2023. The consolidated, audited results were in line with the preliminary results, announced ...
![](https://cdn.snapi.dev/images/v1/p/r/press4-2290520.jpg)
Bavarian Nordic's Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency
COPENHAGEN, Denmark, February 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) (“the Company”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
![](https://cdn.snapi.dev/images/v1/p/r/press3-2285261.jpg)
Bavarian Nordic delivered record financial results in 2023
COPENHAGEN, Denmark, February 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today reports preliminary, unaudited financial results for 2023 and financial guidance for 2024. Furthermore, the Company provi...
![](https://cdn.snapi.dev/images/v1/p/r/press8-2195431.jpg)
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic
COPENHAGEN, Denmark, December 13, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a new long-term incentive program for Executive Management...
![](https://cdn.snapi.dev/images/v1/p/r/press11-2169229.jpg)
Bavarian Nordic to hold Capital Markets Days in February 2024
COPENHAGEN, Denmark, November 22, 2023 – Bavarian Nordic A/S (OMX: BAVA) will hold a series of capital markets days in February 2024 for investors and analysts across Europe and the U.S.
![](https://cdn.snapi.dev/images/v1/p/r/press20-2161068.jpg)
Bavarian Nordic Announces Interim Results for the First Nine Months of 2023
COPENHAGEN, Denmark, November 16, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2023 and business progress for the third quarter of ...